Paper Details

  1. Home
  2. Paper Details

Single High Dose of Liposomal Amphotericin B in Human Immunodeficiency Virus/AIDS-Related Disseminated Histoplasmosis: A Randomized Trial.

Author: AdenisAntoine, BahrNathan C, BayMonica B, BoulwareDavid R, ChillerTom, DamascenoLisandra Serra, FalciDiego R, GodoyCassia S M, GuimarãesMarilia R, GuimarãesTaiguara F, IsraelskiDennis, KistRoger, LanaDaiane Dalla, LeitãoTerezinha do Menino Jesus Silva, MeloMarineide, MonteiroGloria Regina de G, PasqualottoAlessandro C, SilvaLarissa R, SoaresRenata B A, SpecAndrej, VechiHareton T, WiltgenDenusa, de MesquitaJacó R L

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

One-day induction therapy with 10 mg/kg of L-AmB in AIDS-related histoplasmosis was safe. While clinical response may be non-inferior to standard L-AmB therapy, a confirmatory phase III clinical trial is needed. A single induction dose would markedly reduce drug acquisition costs and simplify treatment, which are key points in terms of increased access.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Histoplasmosis is a major AIDS-defining illness in Latin America. Liposomal amphotericin B (L-AmB) is the drug of choice for treatment, but access is restricted due to the high drug and hospitalization costs of the conventional long regimens. METHODS: Prospective randomized multicenter ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10573726/

データ提供：米国国立医学図書館（NLM）

Histoplasmosis: A Single Dose for a Challenging Disease

This research explores the [infectious diseases] landscape and investigates the potential of a single high dose of liposomal amphotericin B (L-AmB) as an effective and safe treatment for disseminated histoplasmosis in patients with HIV/AIDS. The study, a [randomized trial], compared the efficacy and safety of a single dose of L-AmB to a standard multi-dose regimen and a control group receiving no L-AmB. The researchers aimed to find a more convenient and cost-effective treatment option for this challenging and potentially life-threatening infection.

A New Frontier in Treatment: A Single Dose of Hope

The study found that a single dose of 10 mg/kg L-AmB was safe and well-tolerated in patients with HIV/AIDS-related disseminated histoplasmosis. While the clinical response at day 14 was similar across all groups, a single-dose regimen offers the potential for significant cost savings and reduced treatment duration. This suggests that a single-dose regimen might be a promising alternative to the standard multi-dose regimen, providing a more convenient and affordable treatment option. It's like finding a hidden oasis in the desert – a single dose of L-AmB might offer a refreshing and effective solution for patients with disseminated histoplasmosis.

Managing Histoplasmosis: A Multifaceted Approach

This research emphasizes the importance of finding safe and effective treatments for disseminated histoplasmosis, a serious infection that can be particularly challenging in patients with HIV/AIDS. The study's findings suggest that a single-dose regimen of L-AmB might be a promising alternative to the standard multi-dose regimen. Healthcare professionals can work with patients to develop individualized treatment plans that consider the risks and benefits of different treatment options. It's like navigating a vast desert – a comprehensive understanding of the terrain and the available resources is crucial for a safe and successful journey.

Dr. Camel's Conclusion

This research provides promising findings regarding the potential of a single high dose of liposomal amphotericin B (L-AmB) as a safe and effective treatment for disseminated histoplasmosis in patients with HIV/AIDS. While further research is needed to confirm the long-term efficacy and safety of this approach, it offers a potential solution for a challenging infection. This research highlights the ongoing search for more effective and convenient treatment options for individuals facing complex health challenges.

Date :
  1. Date Completed 2023-10-23
  2. Date Revised 2023-11-06
Further Info :

Pubmed ID

37232940

DOI: Digital Object Identifier

PMC10573726

Related Literature

Article Analysis
・Effective treatment of histoplasmosis
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.